Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00943358 | Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults | PHASE1 | COMPLETED | 175 | — | — | Jul 1, 2009 | Dec 1, 2009 | Aug 8, 2012 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Vaccine | ACTIVE_COMPARATOR | adjuvanted influenza vaccine |
| Vaccine 2 | ACTIVE_COMPARATOR | non-adjuvanted vaccine |
| Name | Type | Description |
|---|---|---|
| MF59 H1N1 vaccine | BIOLOGICAL | 3.75-7.5ug dose |
| Plain H1N1 vaccine | BIOLOGICAL | 7.5-15ug |
Inclusion Criteria: 1. Mentally competent adults, who have signed an informed consent form after having received a detailed explanation of the study protocol. 2. Male or female subjects 18-50 years who are either healthy or have a stable medical condition. 3. Able to understand and comply with all ...